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(http://creativecommoFollow-up in many such studies is through linkage to routinely collected, coded health-care data
sets. We evaluated the accuracy of these data sets for dementia case identification.
Methods: We systematically reviewed the literature for studies comparing dementia coding in
routinely collected data sets to any expert-led reference standard. We recorded study characteristics
and two accuracy measures—positive predictive value (PPV) and sensitivity.
Results: We identified 27 eligible studies with 25 estimating PPV and eight estimating sensitivity.
Study settings and methods varied widely. For all-cause dementia, PPVs ranged from 33%–100%,
but 16/27 were .75%. Sensitivities ranged from 21% to 86%. PPVs for Alzheimer’s disease (range
57%–100%) were generally higher than those for vascular dementia (range 19%–91%).
Discussion: Linkage to routine health-care data can achieve a high PPVand reasonable sensitivity in
certain settings. Given the heterogeneity in accuracy estimates, cohorts should ideally conduct their
own setting-specific validation.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Dementia; Alzheimer’s disease; Dementia; Vascular; Clinical coding; Epidemiology; Prospective studies; Cohortstudies; Sensitivity; Positive predictive value; Predictive value of tests1. Introduction
The increasing burden of dementia is a cause for major
public health concern worldwide [1]. Dementias develop
as the result of a complex interplay between genetics,
lifestyle, and environmental factors. The effect of any single
risk factor is therefore likely to be modest, meaning that very
large study populations are required to generate sufficientst: The authors declare no conflicts of interest.
thor. Tel.: 144 (0)7920037769.
.wilkinson@ed.ac.uk
/j.jalz.2018.02.016
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FLA 5.5.0 DTD  JALZ2590_proofcases to study associations of exposures with incident de-
mentia. Furthermore, because the pathological processes un-
derlying dementia begin many years before the symptom
onset [2], prospective, population-based studies that recruit
participants in midlife or earlier will be crucial in under-
standing natural history and in identifying risk factors and
causal exposures.
For prospective, population-based studies to be used for
research into the determinants of dementia, participants
developing dementia (the “cases” in nested case-control or
case-cohort studies) must be identified. One method of doing
so is through linkages to routinely collected, coded health-
care data sets, which are administrative data sets collectedeimer’s Association. This is an open access article under the CC BY license
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T. Wilkinson et al. / Alzheimer’s & Dementia- (2018) 1-142primarily for healthcare purposes, rather than to address spe-
cific research questions (e.g., hospital admissions or national
mortality data) [3]. Such data sets potentially provide a cost-
effective means of identifying disease cases in prospective
studies while minimizing loss to follow-up [4].
Participants who develop dementia during follow-up
must be identified with a high positive predictive value
(PPV); that is, a high proportion of those identified as having
dementia in routinely collected data sets should be true de-
mentia cases. Ideally, to maximize statistical power and
minimize selection bias in the ascertainment of cases, these
sources would also have a high sensitivity, so that a high pro-
portion of all true cases are identified. Specificity and nega-
tive predictive values are less relevant metrics, as specificity
will be high when precise diagnostic codes are used and
negative predictive value, which is related to disease preva-
lence, will be high in population-based studies where most
individuals do not develop the disease of interest.
Hence, a key focus for population-based prospective
studies worldwide is to understand the accuracy of dementia
codes in routinely collected health-care data sets for identi-
fying dementia cases during follow-up. We therefore sought
to systematically identify, evaluate, and summarize all rele-
vant studies of the accuracy of dementia coding within these
data sources.2. Methods
2.1. Study protocol
We prospectively published the protocol for this review
on PROSPERO (www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID5CRD42015027232).2.2. Search strategy
We searched the databases MEDLINE (Ovid), EMBASE
(Ovid), Web of Science (Thomson Reuters), CENTRAL
(Cochrane Library), and PsycINFO (Ovid) for potentially
relevant studies published between 1/1/1990 and 14/09/
2017. We developed the search strategies with assistance
from an information specialist (Supplementary Appendix
A). We also identified relevant studies through personal
communication and reference list searching.2.3. Study selection
We included studies that compared the presence of codes
for dementia and/or its subtypes in any routinely collected
health-care data set to any expert-derived reference standard
for dementia. We excluded studies that only validated one
routinely collected data set against another. Studies had to
report either PPV and/or sensitivity or provide data from
which either could be calculated. We included relevant
studies published in full and as abstracts. We excluded
studies that only assessed Creutzfeldt-Jakob disease becauseFLA 5.5.0 DTD  JALZ2590_proofit is a notifiable disease in many countries. Where two
studies appeared to have overlapping patient populations,
we included the study with the largest sample size, and
where two different coding systems were investigated sepa-
rately, we selected the most recent version. We did not
impose language restrictions on the search, and translated ar-
ticles when necessary. We excluded studies with,10 coded
events, as we considered these to have limited precision.
Studies assessing sensitivity had to be population based (as
opposed to hospital or clinic based) and to have made
comprehensive attempts to ascertain all dementia cases
within that population. We did not impose this restriction
on studies reporting PPV because to investigate PPV, the
cases are obtained from a routinely collected data set, and
the population depends on the data source (for example,
for hospital admissions data, all cases will have been
admitted to hospital). Two authors (T.W. and A.L. or K.B.)
independently screened all abstracts and full-text articles,
resolving any discrepancies through discussion and the
assistance of a third, senior author (C.L.M.S.).2.4. Data extraction
Two authors (A.L. and T.W.) independently extracted
data from the full-text articles of included studies using a
pretested standardized template. We extracted information
on the following: year of publication; year(s) from which
coded data were obtained; country; study population;
mean or median age of dementia cases or, if neither was
available, the age range of participants at recruitment; study
size; the health-care data sets investigated; coding system;
coding position; the reference standard to which the
routinely collected data sets were compared; and the de-
mentia subtypes (such as Alzheimer’s disease [AD] or
vascular dementia) investigated. We defined the study size
for studies investigating PPV as the total number of partic-
ipants with a dementia code (i.e., true positives and false
positives) and for studies investigating sensitivity as the to-
tal number of dementia cases in the population according to
the reference standard (i.e., true positives and false nega-
tives). We contacted study authors to obtain key data items
that were not reported in publications (e.g., sample size or
coding system).2.5. Risk of bias and applicability assessment
We assessed the risk of bias and applicability for included
studies using an adapted Quality Assessment of Diagnostic
Accuracy Studies 2 form [5]. The Quality Assessment of
Diagnostic Accuracy Studies 2 form requires the risk of
bias and applicability to be graded (low, unclear, and high)
across four categories: patient selection, routine data set
used (“index test”), reference standard, and study participant
flow (Supplementary Appendix B). Two authors (A.L. and
T.W.) independently performed the assessments and 14 May 2018  12:53 pm  ce
T. Wilkinson et al. / Alzheimer’s & Dementia- (2018) 1-14 3resolved discrepancies through consensus. To minimize the
risk of study selection bias, we decided to not exclude
studies based on the quality ratings (which are inherently
subjective), but instead to aid interpretation of results by
highlighting those studies, we considered to be at high risk
of bias or of applicability concerns.2.6. Data synthesis
We did not perform ameta-analysis given the heterogene-
ity between study settings and methodologies. Instead, we
performed a descriptive analysis of the study results, dis-
playing the range of values in forest plots for visual interpre-
tation. We calculated 95% confidence intervals by the
Clopper-Pearson (exact) method. We also reported any rele-
vant within-study analyses that evaluated the effects on PPV
or sensitivity of changing a single variable (e.g., selecting
people with a dementia code in the primary position
compared with those with a code in any position). We per-
formed analyses in R (www.r-project.org).Records idenƟfied through database 
searching
(n=8386)
Record
bibliograp
c
Records imported for screenin
(n=8414)
Titles and abstracts screened
(n=7265)
Full-text arƟcles assessed for 
eligibility
(n=95)
Studies included
(n=27)
Fig. 1. Study selec
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3.1. Study characteristics
We included 27 studies [6–32], of which 26 had full
publications [6–8,10–32] and one a published conference
abstract [9]. We obtained further details required for analysis
from the lead author of the abstract. Fig. 1 outlines the selec-
tion process and reasons for study exclusion. Of the 27
included studies, 25 reported PPV [6–30], and eight
reported sensitivity [6,8,9,18,25,26,31,32] (five reported
both). Characteristics of studies reporting PPV and
sensitivity estimates are displayed in Tables 1 and 2, respec-
tively.
All studies were performed in high-income countries:
10 in mainland European countries [7–9,14–18,25,31],
four in the UK [19,28,29,32], 11 in North America
[6,12,13,20–24,26,27,30], and two in Australia [10,11].
Studies varied widely with respect to population
characteristics, data set type, coding system and version,
codes used to select cases, and the reference standard tos idenƟfied through 
hy searching & personal 
ommunicaƟon
(n=28)
g
Irrelevant records excluded
(n=7170)
Full-text arƟcles excluded
(n=68)
11 Not compared to gold standard
10 Data not enƟrely rouƟnely-collected 
12 Data not coded 
4 Only concerns Creutzfeldt-Jakob disease 
coding
7 SensiƟvity study but not populaƟon-based 
or not aƩempted to idenƟfy all cases in a 
populaƟon 
3 Sample size too small (<10) 
6 Duplicate 
4 Overlapping paƟent populaƟon with other 
study
3 Conference abstract of later published 
paper 
4 Review paper
4 No accuracy figure reported or calculable 
Duplicates removed
(n=1149)
tion process.
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Table 1
Studies reporting the positive predictive value of routinely collected data sets for the ascertainment of dementia cases
First author
and publication
year Country Study period Study population Age*
Study
size
Routine
data set
Coding
system Code(s) assessed n
Reference standard and diagnostic criteria if
used
Ostbye 1999 Canada 1991–1996 Population
based
(CSHA)
.65 at
recruitment
240 D ICD 9 331.0, 290.0–290.3,
290.8–290.9, 290.4, 291.2,
291.8, 294.0–294.9,
332.0–332.1, 333.4. 797
Clinical evaluation—DSM III and NINCDS-
ADRDA
Bjertness 1998 Norway 1990–1991 Nursing
home
residents
Mean 85 26 D ICD 9 290.0, 290.1, 331.0 Clinical and neuropathological diagnosis
Romero 2014 Spain 1993–2007 Population
based
(NEDICES)
Mean 82 148 D ICD 9
ICD 10
Unclear y Cognitive screening and clinical
evaluation—DSM IV and NINCDS-
ADRDA
Feldman 2012y Sweden Unclear Population
based
(HARMONY,
KP, and
SNAC-K)
Unclear 1021 D, H ICD 7
ICD 8
ICD 9
ICD 10
304, 305, 306
290, 293.0, 293.1
290.0, 290.1, 290.4, 294.1,
290.8, 290.9, 331.0,
331.1, 331.2, 331.9
F00, F01, F02, F03, G30,
G31.1, G31.8, F05.1
r Dementia diagnoses made in several
population-based studies—DSM IV and
NINCDS-ADRDA
Henderson 2006 Australia 1998–2001 Population
based
Unclear 21 H ICD 10 F00, F01, F051 r Auditor coding of hospital records
Preen 2004 Australia 1991–1996 Population
based
Unclear 11 H ICD 9 Unclear ary Medical record review
Juurlink 2006 Canada 2002–2004 Population
based
Unclear 238 H ICD 10 F03 r Auditor coding of abstracted medical records
Quan 2008 Canada 2003 Population
based
Unclear Unclear H ICD 10 Unclear Coding from medical record
Nielsen 2011 Denmark 2005–2007 Population
based,
immigrants
only
Median 67 57 Hz ICD 10 F00.0-9, G30.0-9, F01.0-9,
F02.0, F03.9
Medical record review—ICD-10, DSM IV,
NINCDS-ADRDA, NINDS-AIREN,
McKhann, and McKeith
Phung 2007 Denmark 2003 Population
based
Mean 81 197 Hz ICD 10 F00.0, F00.1, F00.2, F00.9,
F01.0, F01.1, F01.2,
F01.3, F01.8, F01.9,
F02.0, F03.9, G30.0,
G30.1, G30.8, G30.9
Clinical evaluation—ICD-10 and DSM IV
Salem 2012 Denmark 2008 Population
based, ,65
years recruited
w 195 Hz ICD 10 F00.0-9, G30.0-9, F01.0-9,
F02.0, F03.9, G31.8
Medical record review—ICD-10, DSM IV,
NINCDS-ADRDA, NINDS-AIREN,
McKhann, and McKeith
F
L
A
5
.5
.0
D
T
D

JA
L
Z
2
5
90
_
p
ro
o
f

1
4
M
a
y
2
0
1
8

1
2
:5
3
p
m

ce
T.
W
ilkin
so
n
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
-
(2
0
1
8
)
1
-1
4
4Coding
positio
Any
Any
Primar
Unclea
Unclea
Second
Unclea
Any
Any
Any
Any
Van de
Vorst 2015
Netherlands 2006–2010 Population
based
Median 80 340 Hz ICD 9 290.0, 290.1, 290.3, 290.4,
294.1, 331.0, 331.1, 331.82
Any Medical record review—DSM IV, NINCDS-
ADRDA, NINDS-AIREN, McKeith, and
McKhann
Dahl 2007 Sweden Unclear Population
based
(GENDER)
Mean 75 35 H ICD 8
ICD 9
ICD 10
290.0–290.19
290.0–290.9
F00-F03, G30, F10.7, R54
Unclear Medical record review and cognitive
screening—DSM IV
Brown 2016 UK 1997–2008 Population
based
(MWS)
50–64 at
recruitment
244 H ICD 10 E51.2, F00, F01, F02,
F03, F10.6, F10.7,
G30, G31.0
Unclear GP questionnaire
Bender 2016 USA 2009–2012 Heart
failure
inpatients
Mean 73 44 H ICD 9 Unclear Any Medical record review
Fisher 1992 USA 1984–1985 Population
based
Unclear 91 Hx ICD 9 290.0–290.9, 331.0–331.2 Any Medical record review
Wei 2016 USA Unclear Population
based
Unclear 100 Hz ICD 9 Unclear Unclear Medical record review
Fujiyoshi 2017 USA 2000–2013 Population
based
45–84 at
recruitment
306 H & D ICD 9
ICD 10
290, 294, 331.0, 331.1,
331.2, 331.8, 331.9,
438.0, 780.9
F00, F01, F03, F04,
G30, G31.0, G31.1,
G31.8, G31.9, I69.9, R41
Any Medical and research clinic record review
Jaakkimainen 2016 Canada 2010–2011 Population
based
.65 at
recruitment
Unclear H, I ICD 9
ICD 10
46.1, 290.0, 290.1, 290.2,
290.3, 290.4, 294.x,
331.0, 331.1, 331.5, 331.82
F00.x, F01.x, F02.x, F03.x, G30.x
Unclear Medical record review
Solomon 2014 Finland 1972–2008 Population
based
(CAIDE)
Mean 79 27 H, M ICD 8
ICD 9
ICD 10
290, 290.10
290, 291.2, 292.8, 294.1,
331.0, 331.1, 437.8
F00, F01, F02, F03, F05.1,
F10.73, F11.73, F14.73,
F16.73, F18.73, F19.73, G30
Unclear Cognitive screening and clinical
evaluation—DSM IV and NINCDS-
ADRDA
Taylor 2009 USA 1993–2005 Population
based
(ADAMS)
.70 at
recruitment
303 I ICD 9 331.0, 331.1, 331.2, 331.7,
290.0, 290.1, 290.10,
290.11, 290.1, 209.1,
290.2, 290.2, 290.3,
290.4, 290.4, 290.4,
290.4, 294.0, 294.1,
294.8, 797
Any Medical records and clinical evaluation—
DSM IIIR, DSM IV, NINCDS-ADRDA,
NINDS-AIREN, Lund & Manchester, and
McKeith
Pippenger 2001 USA 1996–1997 Population
based
Unclear 73 O ICD 9 290.0, 290.1, 290.2, 331.0 Unclear Medical record review
Dunn 2005 UK 1992–2002 Population
based
Mean 82 95 P Unclear Unclear Unclear GP questionnaire
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Table 1
Studies reporting the positive predictive value of routinely collected data sets for the ascertainment of dementia cases (Continued )
First author
and publication
year Country Study period Study population Age*
Study
size
Routine
data set
Coding
system Code(s) assessed
Coding
position
Reference standard and diagnostic criteria if
used
Heath 2015 UK Unclear Population
based
40–64 at
recruitment
15 P Read V2 66h.., 6AB.., E00.., E000.,
E0010, E0011, E0012,
E0013, E001z, E002.,
E0020, E0021, E002z,
E003., E004., E0040,
E0041, E0042, E0043,
E004z, E00y., E00z.,
E041., Eu00., Eu000,
Eu001, Eu002, Eu01.,
Eu010, Eu011, Eu012,
Eu013, Eu01y, Eu01z,
Eu02., Eu020, Eu021,
Eu022, Eu023, Eu024,
Eu025, Eu02y, Eu02z,
F110., F1100, F1101,
F111., F112., F116.,
Fyu30
N/A Medical record review—DSM IV
Butler 2012 USA 2000–2009 Population
based
Mean 80 74 P ICD 9 294.8 Unclear Medical record review—DSM IV, NINCDS-
ADRDA, NINDS-AIREN, and Lund &
Manchester
Abbreviations: DNOS, dementia not otherwise specified; D, deaths; H, hospital admissions data; Hz, Hospital admissions and outpatient data set; Hx, Hospital admissions data from an insurance data set; M,
medications or prescriptions data; O, outpatient data; P, primary care data; I, insurance data; ICD, International Classification of Diseases; PPV, positive predictive value; GP, General Practitioner; CSHA, Canadian
Study of Health and Aging; NEDICES, Neurological Diseases in Central Spain; HARMONY, Study of Dementia in Swedish Twins; KP, Kungsholmen Project; SNAC-K, Swedish National Aging and Care Study
in Kungsholmen/Essinge€oarna; CAIDE, Cardiovascular Risk Factors, Aging and Dementia; GENDER, A Study of Older Unlike-Sex Twins; ADAMS, Aging Demographics and Memory Study; MWS, Million
Women Study; DSM, Diagnostic and Statistical Manual; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders
Association, NINDS-AIREN, National Institute of Neurological Disorders and Stroke Association and Association Internationale pour la Receherche et l’Enseignement en Neurosciences; McKeith, McKeith
et al. consensus guidelines for dementia with Lewy bodies (1996); McKhann, McKhann et al. report of the Work Group on Frontotemporal Dementia and Pick’s Disease (2001); Lund & Manchester, criteria
for frontotemporal dementia from Lund and Manchester groups (1994).
NOTE. Some study used clinically modified versions of ICD coding system which extends code length to provide extra detail (i.e., ICD-9-CM); however, for the purposes of dementia coding up to four digits,
these are identical to the original versions.
NOTE. Ampersand (&) between data sets indicates.1 data sets were combined for the analysis, and commas (,) indicate data sets were analyzed separately, producing separate PPV figures. Drug codes were not
provided in either study that assessed medication data sets.
NOTE. Studies ordered by routine data set type.
*Any information given regarding the ages of dementia cases or age at recruitment. Study period: years fromwhich coded data were obtained. Study size corresponds to the number of coded dementia cases (true
positives and false positives).
yAbstract from conference poster presentation only, full study not yet published.
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Table 2
Studies reporting the sensitivity of routinely collected data sets for the ascertainment of dementia cases
First author and
publication year Country Study period
Study
population Age*
Method of dementia case identification or
confirmation and diagnostic criteria if used
Study
size
Routine
data set
Coding
system Code(s) assessed
Coding
position
Ostbye 1999 [6] Canada 1991–1996 Participants from CSHA,
a randomly selected
group of elderly people
across Canada
.65 at
recruitment
Screening followed by neurologic and
neuropsychological examinations—DSM
III and NINCDS-ADRDA
452 D ICD 9 331.0, 290.0–290.3,
290.8–290.9, 290.4,
291.2, 291.8, 294.0–
294.9, 332.0–332.1,
333.4. 797
Any
Romero 2014 [8] Spain 1993–2007 NEDICES survey—a
longitudinal
population-based
survey of people aged
.65 years within three
communities
Mean 82 Cognitive screening followed by clinical
evaluation—DSM IV and NINCDS-
ADRDA
403 D ICD 9
ICD 10
Unclear Primary
Feldman 2012y [9] Sweden Unclear Population-based twin
study (HARMONY)
Unclear Participant screening via telephone or in-
person testing followed by clinical work-
ups—DSM IV and NINCDS-ADRDA
559
526
526
H
D
H & D
ICD7
ICD8
ICD9
ICD10
304, 305, 306
290, 293.0, 293.1
290.0, 290.1, 290.4,
294.1, 290.8, 290.9,
331.0, 331.1, 331.2,
331.9
F00, F01, F02, F03, G30,
G31.1, G31.8, F05.1
Unclear
Jin 2004 [27] Sweden 1987–2000 Participants in SATSA
and OCTO-Twin
studies
Mean 81 Baseline assessment then telephone
screening and clinical evaluation during
follow-up—DSM IV, NINCDS-ADRDA,
and NINDS-AIREN
321
269
321
H
D
H & D
ICD 8
ICD 9
ICD 10
290, 290.10, 290.11,
290.19, 293
290A, 290B, 290E, 290W,
290X, 294B, 331A
A81.0, F00.0, F00.1,
F00.2, F00.9, F01.0,
F01.1, F01.2, F01.3,
F01.8, F01.9, F02.0,
F02.1, F02.3, F02.8,
F03.9, F05.1, G30.0,
G30.1, G30.8, G30.9,
G31.0, G318 A
Any
Newens 1993 [26] UK 1986–1992 Early-onset dementia
cases identified through
hospital records and via
inquires to social
services, day hospitals,
psychiatric nurses,
nursing homes,
psychologists, general
practitioners, and
neuroradiology centers
40–64 at
recruitment
Medical record review and clinical algorithm 257 D ICD 9 Unclear Any
(Continued )
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Table 2
Studies reporting the sensitivity of routinely collected data sets for the ascertainment of dementia cases (Continued )
First author and
publication year Country Study period
Study
population Age*
Method of dementia case identification or
confirmation and diagnostic criteria if used
Study
size
Routine
data set
Coding
system Code(s) assessed
Coding
position
Solomon 2014 [14] Finland 1972–2008 CAIDE study-derived
from 4 population-
based random samples
Mean 79 Cognitive screening followed by clinical
evaluation and then case conference—
DSM IV and NINCDS-ADRDA
51
52
H
M
ICD 8
ICD 9
ICD 10
290, 290.10
290, 2912A, 2928C,
2941A, 3310A, 3311A,
4378A
F00, F01, F02, F03, F05.1,
F10.73, F11.73,
F14.73, F16.73,
F18.73, F19.73, G30
Unclear
Dahl 2007 [16] Sweden Unclear Unlike-sex twins born
between 1916–1925
and both twins alive at
1995 identified through
Swedish Twin Registry
Mean 75 Cognitive screening and medical record
review and then case conference—DSM
IV
87 H ICD 8
ICD 9
ICD 10
290.0–290.19
290.A–290.X
F00-F03, G30, F10.7, R54
Unclear
Taylor 2009 [22] USA 1993–2005 ADAMS study—a
stratified random
sample of respondents
to the Health and
Retirement Study
.70 at
recruitment
Medical record review, informant history, and
clinical evaluation—DSM IIIR, DSM IV,
NINCDS-ADRDA, NINDS-AIREN,
Lund & Manchester, and McKeith
275 I ICD 9 331.0, 331.1, 331.2,
331.7, 290.0, 290.1,
290.10, 290.11, 290.12,
209.13, 290.20, 290.21.
290.3, 290.40, 290.41,
290.42, 290.43, 294.0,
294.1, 294.8, 797
Any
Abbreviations: H, hospital admissions; D, deaths; M, medications or prescriptions; I, insurance; H &D, hospital and death data combined; ICD, International Classification of Diseases; CSHA, Canadian Study
of Health &Ageing; NEDICES, Neurological Diseases in Central Spain; HARMONY, Study of Dementia in Swedish Twins; SATSA, Swedish Twin Registry who took part in the Swedish Adoption/Twin Study of
Ageing; OCTO-Twin, Origins of Variance in the Oldest Old; CAIDE, Cardiovascular Risk Factors, Aging and Dementia; ADAMS, Aging Demographics and Memory Study; DSM, Diagnostic and Statistical
Manual; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; NINDS-AIREN, National Institute of
Neurological Disorders and Stroke Association and Association Internationale pour la Receherche et l’Enseignement en Neurosciences; McKeith, McKeith et al. consensus guidelines for dementia with Lewy
bodies (1996); McKhann, McKhann et al. report of the Work Group on Frontotemporal Dementia and Pick’s Disease (2001); Lund &Manchester, criteria for frontotemporal dementia from Lund and Manchester
groups (1994).
NOTE. Drug codes not available for study that assessed medications data set.
NOTE. Some studies used clinically modified versions of ICD coding system which extends code length to provide extra detail (i.e., ICD-9-CM); however, for the purposes of dementia coding up to four digits,
these are identical to the original versions.
NOTE. Study period: years from which coded data were obtained. Study size: total number of patients known to have dementia (true positives and false positives combined).
NOTE. Studies ordered by routine data set type.
*Any information given regarding the ages of dementia cases or age at recruitment. Studies either attempted to ascertain all dementia cases within a cohort of participants, or attempted to ascertain all dementia
cases within a geographical population and then verified these diagnoses.
yAbstract from conference poster presentation only, full study not yet published.
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T. Wilkinson et al. / Alzheimer’s & Dementia- (2018) 1-14 9which coded data were compared. Most studies identified
cases from a defined general population, but one involved
nursing home residents [7], and another was of hospital-
ized patients with heart failure [20]. Only 12 of the 27
studies reported the average age of dementia cases (range
58–85 years), while a further seven only stated the ages
of participants at recruitment. Most studies investigated
hospital data (variably including hospital admissions
with or without outpatient appointments) or death data
[6–25,27,31,32]. Two studies assessed insurance data
[24,26], three assessed primary care data [28–30], and
one assessed prescription data [25].
Studies investigated all-cause dementia [6–11,13–32], AD
[6,9,15,16,23,25,26,31], vascular dementia [6,9,15–17,23,31],
or unspecified dementia only [12]. No studies investigated
other dementia subtypes, such as frontotemporal dementia
or dementia with Lewy Bodies. Studies varied in the
codes selected to identify dementia and subtype cases
(Supplementary Appendix C).
The reference standards to which coded data were
compared varied. They could be broadly categorized as fol-
lows: direct clinical evaluation [6,7,9,15,26], cognitive
screening followed by clinical evaluation [8,25,31],
medical record review [10–14,16–18,20–24,27,29,30,32],
or a General Practitioner questionnaire [19,28].Fig. 2. PPVestimates for routinely collected coded health data to identify all-caus
cases with 1 dementia codes in data set. *High risk of bias or applicability conce
confidence interval.
FLA 5.5.0 DTD  JALZ2590_proof3.2. Quality assessment
Only five studies [15,17,18,23,24] were judged as having
a low risk of bias and applicability concerns across all
categories (Supplementary Appendix D). Most studies had
one or more “unclear” ratings across categories, either
because information was not provided or was unclear in
the publication. Eight studies that assessed PPV had a high
risk of bias or applicability concerns in one or more areas
[7,14,16,19,20,22,29,30], but no studies of sensitivity were
so affected.3.3. PPV–all-cause dementia
For all-cause dementia, there were 27 PPV estimates in
total (Fig. 2). Four studies reported the PPV for dementia
coding in mortality data [6–9], 10 in hospital admissions
data bib10[9–13,17,18,20,24,25], six in hospital
admissions and outpatient data combined [14–
17,19,21,22], one in hospital admissions and mortality
combined [23], one in outpatient data [27], two in insurance
data [24,26], and three in primary care data [28–30].
Although results varied widely, with PPVs ranging from
33%–100% across all studies, 16 of the 27 PPV estimates
were .75%. Of the eight studies at high risk of bias, foure dementia cases, stratified by type of routine data set. Study size: number of
rns in one or more areas. Abbreviations: PPV, positive predictive value; CI,
 14 May 2018  12:53 pm  ce
Fig. 3. PPVestimates for routinely collected coded health data to identify dementia subtype cases, stratified by type of routine data set. Study size: number of
cases with 1 dementia codes in data set. *High risk of bias or applicability concerns in one or more areas. Abbreviations: AD, Alzheimer’s disease; VaD,
vascular dementia; PPV, positive predictive value; CI, confidence interval.
T. Wilkinson et al. / Alzheimer’s & Dementia- (2018) 1-1410reported very high PPVs [7,20,29,30], and one reported a
low PPV of 35% [14], raising the possibility that results at
the extremes of the range of reported estimates may be partly
due to bias. Visual inspection of the forest plot revealed no
clear differences between data set types. The three primary
care studies reported PPVs of 83%, 92%, and 100% [28–
30]. There was no clear difference between studies when
stratified by the method of reference standard used
(Supplementary Appendix E).3.4. PPV–Alzheimer’s disease and vascular dementia
There were 10 estimates of PPV for coding for AD
[6,9,15,16,23,25,26,31] and eight for vascular dementia
[6,9,15–17,23,31] (Fig. 3). PPVs for AD (range 57%–
100%) were generally higher and less variable than those
for vascular dementia (range 19%–91%). Six studies pro-
vided estimates of PPV for AD and vascular dementia
[6,9,15,16,23,31]. Five of these found a higher PPV for
coding of AD compared with vascular dementia. A single
study of the accuracy of using codes for prescriptions of
AD medications to identify AD cases reported a high PPV
(97%) [25].FLA 5.5.0 DTD  JALZ2590_proof3.5. Sensitivity–all-cause dementia
The 12 estimates of sensitivity for all-cause dementia
ranged from 21%–86%, with only three studies reporting es-
timates .60% (Fig. 4). The only study investigating insur-
ance data reported the highest sensitivity (86%), likely
reflecting the comprehensive coverage of this data source
[26]. The lowest sensitivity (21%) came from a study which
only selected codes in the primary position on the death cer-
tificate [8]. There were no clear overall differences in sensi-
tivity of hospital and mortality data, but two studies
demonstrated higher sensitivities from combining hospital
admissions and mortality data compared with either source
alone, increasing from 48% and 28% in mortality data and
from 40% and 43% in hospital admissions data to 62%
and 52% in both sources combined [9,31].3.6. Within-study analyses
Supplementary Appendix F shows results of 10 within-
study analyses from seven studies [6,8,15,17,19,21,32]. In
general, sample sizes were small, resulting in broad
confidence intervals. Selecting codes only in the primary
versus any other position gave a higher PPV but, 14 May 2018  12:53 pm  ce
Fig. 4. Sensitivity estimates for routinely collected coded health data to identify all-cause dementia cases, stratified by type of routine data set. Study size:
Number of known dementia cases for which a code was sought. Abbreviation: CI, confidence interval.
T. Wilkinson et al. / Alzheimer’s & Dementia- (2018) 1-14 11unsurprisingly, at a cost to sensitivity, with fewer cases
identified [6,21,32]. The results of two studies suggested
that relying on codes that refer to dementia subtypes (such
as AD and/or vascular dementia) to identify any dementia
case (not necessarily that subtype) produced a higher PPV
than using general dementia codes but with fewer cases
identified [6,15]. In keeping with the positive association
between PPV and disease prevalence, one study
demonstrated a lower PPV for patients ,65 versus
65 years of age (PPV 68% and 96%, respectively) [17].
One study reported that death certificates identified moderate
or severe dementia with a higher sensitivity than mild demen-
tia [8]. Finally, one study found that patientswith2 dementia
codes in hospital admissions dataweremore likely to have de-
mentia than those with only one code (PPV 94% vs. 68%,
respectively) [19].
4. Discussion
4.1. Summary of findings
In this systematic review, we found wide variation in the
results of validation studies of dementia coding in routinely
collected health-care data sets, at least partly reflecting the
heterogeneity in study methodologies, settings, and the
data sets they assessed. Importantly, however, we found
that in some settings, these data sets can achieve high
PPVs of .80%–90%. By contrast, the sensitivity of theFLA 5.5.0 DTD  JALZ2590_proofdata sets investigated to date is lower, with many data sour-
ces identifying ,50% of all dementia cases.
For all-cause dementia, primary care data appears to
identify cases with a high PPV [28–30]. Combining
hospital and death data produces a reasonable sensitivity
for all-cause dementia [9,31], and, of the data sources
assessed, the US insurance data produces the highest
sensitivity [26]. For identifying AD cases, PPV is reassur-
ingly high across most studies and appears to be particularly
high in medications data [25] and combined US hospital and
mortality data [23].
There is no widely accepted minimum level of accuracy
for disease case ascertainment in prospective studies. The
level of accuracy that is considered acceptable is likely
to differ according to the study setting, and there will inev-
itably be a trade-off between PPV and sensitivity. For
example, large prospective studies are likely to be best
served by data sources which achieve a high PPV even if
these data sets have a lower sensitivity, as the number of
false positives (controls misidentified as dementia cases)
must be minimized to reduce bias and distortion of risk es-
timates [33]. A high sensitivity is less crucial because the
effects of false negatives (cases misidentified as controls)
would be diluted among the large control population. A
reasonable sensitivity is still required, however, to ensure
that the cases ascertained are representative and to maxi-
mize statistical power. 14 May 2018  12:53 pm  ce
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the wide variation in PPV estimates. For example, the two
studies with the lowest PPV estimates investigated only a
single code (F03—unspecified dementia) and an ethnic mi-
nority population, respectively [12,14]. In one of these, the
PPV was likely to have been further lowered by high rates
of “indeterminate” cases due to the particularly strict
reference standard requirements [14]. By contrast, one study
with the joint-highest PPV involved nursing home residents
only, a population with a high prevalence of dementia, which
will increase PPVs because of the positive association be-
tween PPV and disease prevalence [7]. Furthermore, the
reference standards used varied widely with respect to
which, if any, diagnostic criteria were employed and whether
the diagnosis was made by screening followed by in-person
evaluation, medical record review, General Practitioner
questionnaire, or another method.
The sensitivity of routine data sets for identifying demen-
tia cases appeared lower than that of some other neurodegen-
erative diseases, such as motor neurone disease [34]. Key
differences between these conditions may explain the lower
sensitivity of dementia coding. First, it is recognized that a
significant proportion of dementia cases are undiagnosed
and so missing from routine data sets [35,36]. This is less
of an issue for conditions such as motor neurone disease
that result in rapidly progressive physical symptoms.
Second, for patients with a diagnosis of dementia, their
dementia may not be the primary reason for admission to
hospital, meaning it may not be mentioned in hospital
discharge summaries and so omitted from hospital
admissions data [37]. However, the sensitivity of routinely
collected health-care data is changing over time. For
example, a UK clinic-based study reported an improvement
in the sensitivity of mortality data for dementia from 40% to
63% between 2006 and 2013, probably reflecting a changing
awareness and desire to diagnose dementia in health profes-
sionals, patients, and caregivers over time [38].4.2. Future directions—improving accuracy of dementia
identification
Given that management of dementia is predominantly
community based, primary care data sets may provide an op-
portunity to identify cases that do not appear in hospital ad-
missions or mortality data. Three small studies reported on
the PPV of primary care data sets, and these suggested that
primary care data may identify dementia cases with a high
PPV, in keeping with our previous findings that primary
care can be an accurate data source for other neurodegener-
ative diseases [34]. This warrants further investigation. Our
review also identified a need for studies of the accuracy of
routinely collected health-care data to identify dementia
subtypes other than AD or vascular dementia (e.g., fronto-
temporal dementia or dementia with Lewy bodies).
The use of medication prescription data to identify AD
cases is an under-investigated area, but one small study re-FLA 5.5.0 DTD  JALZ2590_proofported a promising PPV of 97% [25]. Dementia drugs such
as cholinesterase inhibitors are now commonly prescribed
for patients with dementia with Lewy bodies and for AD
and therefore medication data alone may not be sufficiently
accurate to identify dementia subtypes. Although the indica-
tions for these medications are relatively specific to demen-
tia, they may be used in other conditions, such as memantine
for migraine [39]. Future studies with larger sample sizes
would allow further evaluation of medication data to identify
AD and all-cause dementia.
Cohorts may wish to link to several different data sets to
increase sensitivity. To date, only hospital admissions and
death registrations have been evaluated in combination.
Studies investigating the accuracy of using combinations
of data sets (e.g., primary care, hospital admissions, and
death data together) are required to pursue this further.
Case detection algorithms need to achieve an appropriate
balance between the proportion of cases that are true posi-
tives (high PPV) and comprehensive case ascertainment
(high sensitivity). Results from the within-study analyses re-
ported here provide some possible mechanisms through
which cases can be identified with a high PPV. For example,
we found higher PPVs when all-cause dementia cases were
identified using codes for dementia subtypes compared with
general dementia codes [6,15,19], by selecting dementia
codes in the primary position rather than other positions
[6,21], or by requiring a dementia diagnosis code to occur
in 2 rather than only one hospital admission [19]. Howev-
er, in each of these studies, the use of these techniques to in-
crease PPV reduced the number of cases identified.
One method of maximizing both PPV and sensitivity
may be to use a broad code list to identify cases from
routinely collected data, followed by an examination of
the full-text medical records to select participants who
truly have dementia. Whereas, this would be time
consuming to do manually in a large study, the use of nat-
ural language processing to confirm diagnoses of dementia
from free-text records holds promise [40]. One study found
that combining natural language processing with coded
data produced a PPV of 92% [41].4.3. Strengths and limitations
We used rigorous systematic review methodology to
maximize the validity of our results. This included prospec-
tive protocol publication; detailed search criteria; and dupli-
cation of study screening, quality assessments, and data
extraction by two authors.
There were some limitations however. First, Quality
Assessment of Diagnostic Accuracy Studies 2 assessment
showed that studies were of variable quality with some
risk of bias. Second, publication bias (with a possible ten-
dency to publish results demonstrating good accuracy)
may also have influenced our results. We did not attempt
to quantify this due to the absence of a robust technique
for doing so in test accuracy reviews [42]. Third, PPV 14 May 2018  12:53 pm  ce
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with a higher prevalence of dementia (older populations
and care home residents) will inevitably result in higher
PPVs. We could not formally adjust for the underlying
prevalence of dementia in the study populations, but rather
attempted to take this into account in interpreting the re-
sults. Fourth, we included all relevant studies published
since 1990, but results from the older studies among these
may be of less contemporary relevance because perceptions
and diagnostic boundaries of dementia have changed over
time. Fifth, many studies reported a relatively young
average age of dementia cases (e.g., ,80 years), limiting
the generalizability of the findings to studies ascertaining
dementia in the oldest old.
A major source of heterogeneity in validation studies, and
therefore a limitation of our systematic review, is the varia-
tion in the reference standards to which the coded data were
compared. This reflects the complexities of dementia diag-
nosis and the lack of a robust “gold standard” for confirma-
tion of cases in dementia research [43]. Although we did not
see a pattern in reported PPVs when stratifying by reference
standard, it is highly likely that the method of case confirma-
tion will affect study estimates. Similarly, studies differed on
whether diagnostic criteria were applied during validation,
and the use of strict diagnostic criteria is likely to affect
the study estimates. Future studies will need to carefully
consider the reference standard used and could consider re-
porting a “best case” and “worst case” PPV, based on how
strictly diagnostic criteria are applied.5. Conclusion
Although no replacement for in-person, comprehensive
clinical assessment, routinely collected health-care data
sets have the potential to be a cost-effective and comprehen-
sive method of identifying dementia cases in prospective
studies. Given the marked heterogeneity between existing
validation studies, cohorts should ideally validate these
data sets using their own data so that the accuracy is known
for their specific study population and setting. Dementia
subtypes, primary care, prescribing data, and the develop-
ment of algorithms to maximize accuracy are potentially
useful and under-investigated areas for further research.Acknowledgments
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RESEARCH IN CONTEXT1. Systematic review: We searched the databases
MEDLINE, EMBASE, Web of Science, CENTRAL,
and PsycINFO for studies in which the coding of de-
mentia cases in routinely collected data sets was
compared with an expert-led reference standard
and either positive predictive value (PPV) or sensi-
tivity estimates were reported or calculable.
2. Interpretation: We found a wide range of methodolo-
gies used by validation studies. Most studies vali-
dated hospital and/or death data, three investigated
primary care data, two evaluated insurance data,
and single studies assessed prescription and outpa-
tient data. Reported estimates for PPVand sensitivity
varied widely, but many studies achieved high PPV
and/or reasonable sensitivity. Coding for Alz-
heimer’s disease had generally higher and more
consistent PPVs than for vascular dementia.
3. Future directions: Identification of dementia sub-
types, the accuracy of primary care and prescription
data, and the development of algorithms to maximize
accuracy are promising but under-investigated areas
for future research.
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